TWI523946B - 位置特異性整合 - Google Patents
位置特異性整合 Download PDFInfo
- Publication number
- TWI523946B TWI523946B TW102122188A TW102122188A TWI523946B TW I523946 B TWI523946 B TW I523946B TW 102122188 A TW102122188 A TW 102122188A TW 102122188 A TW102122188 A TW 102122188A TW I523946 B TWI523946 B TW I523946B
- Authority
- TW
- Taiwan
- Prior art keywords
- gene
- cell
- sequence
- host cell
- nucleotide sequence
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261663147P | 2012-06-22 | 2012-06-22 | |
| EP12185330.3A EP2711428A1 (en) | 2012-09-21 | 2012-09-21 | Site-specific integration |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW201420762A TW201420762A (zh) | 2014-06-01 |
| TWI523946B true TWI523946B (zh) | 2016-03-01 |
Family
ID=46888327
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW102122188A TWI523946B (zh) | 2012-06-22 | 2013-06-21 | 位置特異性整合 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US10280436B2 (enExample) |
| EP (2) | EP2711428A1 (enExample) |
| JP (1) | JP6053923B2 (enExample) |
| KR (1) | KR101761709B1 (enExample) |
| CN (1) | CN104379753B (enExample) |
| AU (1) | AU2013279333C1 (enExample) |
| BR (1) | BR112014032299B1 (enExample) |
| CA (1) | CA2876280C (enExample) |
| DK (1) | DK2864489T3 (enExample) |
| EA (1) | EA034039B1 (enExample) |
| ES (1) | ES2629509T3 (enExample) |
| IL (1) | IL236347A0 (enExample) |
| IN (1) | IN2014MN02518A (enExample) |
| MX (1) | MX351727B (enExample) |
| PL (1) | PL2864489T3 (enExample) |
| SG (1) | SG11201408576QA (enExample) |
| TW (1) | TWI523946B (enExample) |
| WO (1) | WO2013190032A1 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201407852D0 (en) | 2014-05-02 | 2014-06-18 | Iontas Ltd | Preparation of libraries od protein variants expressed in eukaryotic cells and use for selecting binding molecules |
| US10774353B2 (en) * | 2015-04-27 | 2020-09-15 | Momenta Pharmaceuticals, Inc. | Methods of manufacturing therapeutic proteins |
| ES2823173T3 (es) | 2016-01-27 | 2021-05-06 | Just Biotherapeutics Inc | Promotor híbrido y usos del mismo |
| US11261462B2 (en) | 2016-01-27 | 2022-03-01 | Just-Evotec Biologics, Inc. | Inducible expression from transposon-based vectors and uses |
| US11098310B2 (en) | 2016-01-27 | 2021-08-24 | Just-Evotec Biologics, Inc. | Expression from transposon-based vectors and uses |
| US11530277B2 (en) | 2016-04-20 | 2022-12-20 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for making antibodies based on use of an expression-enhancing locus |
| BR112018071283A2 (pt) * | 2016-04-20 | 2019-02-12 | Regeneron Pharma | célula, conjunto de vetores para expressar uma proteína de ligação a antígeno biespecífica em uma célula, conjunto de vetores, método, e, método para produção de uma proteína de ligação a antígeno. |
| CN119242587A (zh) * | 2017-02-17 | 2025-01-03 | 隆萨有限公司 | 难以表达的蛋白质的多位点特异性整合细胞 |
| WO2018150271A1 (en) | 2017-02-17 | 2018-08-23 | Lonza Ltd. | Mammalian cells for producing adeno-associated viruses |
| GB201703418D0 (en) * | 2017-03-03 | 2017-04-19 | Ge Healthcare Bio Sciences Ab | Method for cell line development |
| WO2018167621A1 (en) | 2017-03-16 | 2018-09-20 | Pfizer Inc. | Tyrosine prototrophy |
| CN107557390A (zh) * | 2017-09-18 | 2018-01-09 | 江南大学 | 一种筛选cho细胞系高表达位点的方法 |
| IL275462B2 (en) * | 2017-12-22 | 2026-01-01 | Genentech Inc | Targeted integration of nucleic acids |
| JP7549582B2 (ja) * | 2018-10-01 | 2024-09-11 | ロンザ リミテッド | 予測可能かつ安定な導入遺伝子発現を有するｓｓｉ細胞および形成の方法 |
| KR102559149B1 (ko) | 2018-10-26 | 2023-07-24 | 에프. 호프만-라 로슈 아게 | 재조합효소 매개 카세트 교환을 이용한 다중특이적 항체 스크리닝 방법 |
| EP3980544A1 (en) * | 2018-12-21 | 2022-04-13 | F. Hoffmann-La Roche AG | Targeted integration of nucleic acids |
| SG11202110076PA (en) * | 2019-04-02 | 2021-10-28 | Chugai Pharmaceutical Co Ltd | Method of introducing target-specific foreign gene |
| WO2021094461A1 (en) | 2019-11-14 | 2021-05-20 | Lonza Ltd | Methods of cell selection |
| KR102335242B1 (ko) * | 2020-05-22 | 2021-12-02 | 인천대학교 산학협력단 | Fer1L4 유전자에 부위-특이적 통합된 RMCE 랜딩 패드를 포함하는 CHO 세포 |
| WO2022023972A1 (en) | 2020-07-30 | 2022-02-03 | Pfizer Inc. | Cells having gene duplications and uses thereof |
| US20240327496A1 (en) | 2021-08-02 | 2024-10-03 | Pfizer Inc. | Improved Expression Vectors and Uses Thereof |
| AR127674A1 (es) | 2021-10-18 | 2024-02-21 | Regeneron Pharma | Células de mamífero que comprenden genes cas9 integrados para producir sitios de integración estables, y células de mamífero que comprenden sitios de integración estables y otros sitios |
| JP2024537896A (ja) | 2021-10-18 | 2024-10-16 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | アデノウイルス随伴ウイルスポリヌクレオチドを含む真核細胞 |
| EP4473096A1 (en) | 2022-02-02 | 2024-12-11 | Pfizer Inc. | Cysteine prototrophy |
| CN118726475B (zh) * | 2023-03-28 | 2025-07-08 | 深圳太力生物技术有限责任公司 | 核酸、重组载体、靶向整合细胞、基因表达方法和应用 |
| CN119955730A (zh) * | 2023-11-08 | 2025-05-09 | 深圳太力生物技术有限责任公司 | 一种细胞株及其制备方法与应用 |
| WO2025115876A1 (ja) | 2023-11-29 | 2025-06-05 | 富士フイルム株式会社 | 細胞の作出方法、細胞及びタンパク質の製造方法 |
| KR20260103112A (ko) | 2023-11-29 | 2026-07-02 | 후지필름 가부시키가이샤 | 탐색 방법, 세포의 작출 방법, 세포의 선별 방법, 세포 및 세포 생산물의 제조 방법 |
| WO2026162509A1 (en) | 2025-01-28 | 2026-08-06 | Selexis Sa | Integration regions and uses thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2646438B1 (fr) | 1989-03-20 | 2007-11-02 | Pasteur Institut | Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration |
| WO1998048005A1 (en) | 1997-04-24 | 1998-10-29 | University Of Washington | Targeted gene modification by parvoviral vectors |
| JP4926054B2 (ja) * | 2004-07-20 | 2012-05-09 | シムフォゲン・アクティーゼルスカブ | 抗−ＲｈＤ組換えポリクローナル抗体及び製造方法 |
| JP4665115B2 (ja) * | 2004-08-06 | 2011-04-06 | 独立行政法人理化学研究所 | 骨・関節疾患感受性遺伝子およびその用途 |
| EP1913149A4 (en) | 2005-07-26 | 2009-08-05 | Sangamo Biosciences Inc | TARGETED INTEGRATION AND EXPRESSION OF EXOGENOUS NUCLEIC ACID SEQUENCES |
-
2012
- 2012-09-21 EP EP12185330.3A patent/EP2711428A1/en not_active Withdrawn
-
2013
- 2013-06-20 EP EP13729962.4A patent/EP2864489B1/en active Active
- 2013-06-20 BR BR112014032299-6A patent/BR112014032299B1/pt not_active IP Right Cessation
- 2013-06-20 WO PCT/EP2013/062859 patent/WO2013190032A1/en not_active Ceased
- 2013-06-20 PL PL13729962T patent/PL2864489T3/pl unknown
- 2013-06-20 DK DK13729962.4T patent/DK2864489T3/en active
- 2013-06-20 EA EA201590068A patent/EA034039B1/ru not_active IP Right Cessation
- 2013-06-20 SG SG11201408576QA patent/SG11201408576QA/en unknown
- 2013-06-20 ES ES13729962.4T patent/ES2629509T3/es active Active
- 2013-06-20 CA CA2876280A patent/CA2876280C/en active Active
- 2013-06-20 CN CN201380032837.8A patent/CN104379753B/zh active Active
- 2013-06-20 US US14/409,283 patent/US10280436B2/en active Active
- 2013-06-20 MX MX2014015612A patent/MX351727B/es active IP Right Grant
- 2013-06-20 KR KR1020157000511A patent/KR101761709B1/ko active Active
- 2013-06-20 JP JP2015517758A patent/JP6053923B2/ja active Active
- 2013-06-20 AU AU2013279333A patent/AU2013279333C1/en not_active Ceased
- 2013-06-20 IN IN2518MUN2014 patent/IN2014MN02518A/en unknown
- 2013-06-21 TW TW102122188A patent/TWI523946B/zh not_active IP Right Cessation
-
2014
- 2014-12-18 IL IL236347A patent/IL236347A0/en active IP Right Grant
-
2018
- 2018-10-31 US US16/176,525 patent/US11326185B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11326185B2 (en) | Site-specific integration | |
| US12503520B2 (en) | Compositions and methods for making antibodies based on use of an expression-enhancing locus | |
| US12528883B2 (en) | Compositions and methods for making antibodies based on use of expression-enhancing loci | |
| Zhang et al. | Recombinase‐mediated cassette exchange (RMCE) for monoclonal antibody expression in the commercially relevant CHOK1SV cell line | |
| KR20100097123A (ko) | 신규한 재조합 서열 | |
| KR20190056378A (ko) | Hspa5 유전자의 프로모터 | |
| US11136598B2 (en) | Method for cell line development | |
| HK1202580B (en) | Site-specific integration | |
| KR101634244B1 (ko) | Talen을 이용하여 grk5 넉아웃 마우스를 제조하는 방법 | |
| EP4688815A1 (en) | Cho cells with optimized host cell protein profile | |
| AU2023258798A1 (en) | PROMOTER OF Eno1 GENE | |
| CN120005831A (zh) | Cho整合位点及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Annulment or lapse of patent due to non-payment of fees |